Studies in KRAS mutant models of lung cancer demonstrated that the combination of MEK and CDK4/6 inhibitors lead to TIS, whereas components of SASP attracted NK cells, contributing to tumour regression98. The gene discussed is MAP2K7; the disease is neoplasm.